Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks

Stock Research Monitor: AMPE, ANTH, and ARLZ

LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration. In today’s pre-market research, WallStEquities.com recalls the performance of the following stocks: Amicus Therapeutics Inc. (NASDAQ: FOLD), Ampio Pharmaceuticals Inc. (NYSE AMER: AMPE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ). These equities are part of the Biotechnology industry, which is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include medical, agricultural, environmental, and industrial. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Amicus Therapeutics

On Tuesday, shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. recorded a trading volume of 2.23 million shares. The stock ended at $15.54, declining 1.33% from the last trading session. The Company’s shares have gained 11.00% in the last month, 2.78% over the previous three months, and 84.78% over the past year. The stock is trading above its 50-day and 200-day moving averages by 7.59% and 8.91%, respectively. Furthermore, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 57.07.

On May 08th, 2018, Amicus Therapeutics announced its results for Q1 2018. Total revenue in Q1 2018 was $16.7 million, total operating expenses were $70.3 million, net cash spend was $48.0 million, and net loss was $49.9 million. At March 31st, 2018, cash, cash equivalents, and marketable securities totaled $605.2 million. Get the full research report on FOLD for free by clicking below at:

www.wallstequities.com/registration/?symbol=FOLD

Ampio Pharmaceuticals

Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.’s stock finished yesterday’s session 10.21% lower at $2.11. A total volume of 1.57 million shares was traded, which was above their three months average volume of 836,660 shares. The Company’s shares have surged 158.48% over the past year. The stock is trading above its 200-day moving average by 6.92%. Furthermore, shares of Ampio Pharma, which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the US, have an RSI of 25.48.

On May 02nd, 2018, Ampio Pharma announced that the publication titled, “Intra-articular injection of the anti-inflammatory compound LMWF-5A (Ampion™) in adults with severe osteoarthritis: a double-blind prospective randomized controlled multicenter safety and efficacy trial,” authored by Dr. Brian Cole, MD; Kristin Salottolo, MPH; and Dr. David Bar-Or, MD, was accepted for publication to the peer-reviewed journal, Patient Safety in Surgery. This publication summarizes the latest AP-003-C pivotal trial results on severe osteoarthritis of the knee patients. The free technical report on AMPE can be accessed at:

www.wallstequities.com/registration/?symbol=AMPE

Anthera Pharmaceuticals

At the close of trading on Tuesday, shares in Hayward, California headquartered Anthera Pharmaceuticals Inc. saw a slight decline of 0.84%, ending the day at $0.28. The stock recorded a trading volume of 690,989 shares. The Company’s shares are trading 16.61% below their 50-day moving average. Moreover, shares of Anthera Pharma, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have an RSI of 32.71. Sign up for free on Wall St. Equities and claim the latest report on ANTH at:

www.wallstequities.com/registration/?symbol=ANTH

Aralez Pharmaceuticals

Mississauga, Canada headquartered Aralez Pharmaceuticals Inc.’s shares ended the day 2.73% higher at $0.38 with a total trading volume of 1.16 million shares. The stock is trading 70.60% below its 50-day moving average. Shares of the Company, which operates as a specialty pharmaceutical company in the US and Canada, have an RSI of 21.87.

On May 08th, 2018, Aralez Pharma (ARLZ) announced its results Q1 2018. Total revenues for Q1 2018 were $38.1 million, net loss was $19.7 million, and adjusted EBITDA was $4.9 million. As of March 31st, 2018, approximately 67 million of ARLZ’s common shares were issued and outstanding, and the Company had cash and cash equivalents of approximately $43.9 million. See the free research coverage on ARLZ at:

www.wallstequities.com/registration/?symbol=ARLZ

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 500602